Ignite Creation Date:
2025-12-25 @ 12:16 AM
Ignite Modification Date:
2026-02-22 @ 4:13 PM
Study NCT ID:
NCT01718158
Status:
COMPLETED
Last Update Posted:
2015-10-09
First Post:
2012-10-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-01
Start Date Type:
None
Primary Completion Date:
2014-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-10
Completion Date Type:
ACTUAL
First Submit Date:
2012-10-29
First Submit QC Date:
None
Study First Post Date:
2012-10-31
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2015-10-09
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2015-09-23
Last Update Post Date:
2015-10-09
Last Update Post Date Type:
ESTIMATED